Página 1 desde 73 resultados
The sequence listing in the file named "67858o707001v3.txt" having a size of 342,545 bytes that was created Jun. 13, 2012 is hereby incorporated by reference in its entirety.
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention is an extension of Applicants' prior invention disclosed
This invention relates to therapeutic compositions which comprise iron ions and to their medical applications.
An adequate supply of iron to the body is an essential requirement for tissue growth and the maintenance of good health in both man and animals. Moreover, in certain pathological conditions
BACKGROUND
It has been reported that pain is most often the principal reason for pediatric patients to seek medical treatment. Pain management in children is a significant clinical problem. Post-operative pain or surgical pain is one type of pain that is sometimes undertreated to avoid potentially
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a U.S. national stage application filed under 35 U.S.C. .sctn.371 of International Patent Application PCT/EP2006/003106, accorded an international filing date of Apr. 5, 2006, which claims the benefit of Italian Patent Application No.
The present invention relates generally to phosphatidylinositol 3-kinase (PI3K) enzymes, and more particularly to selective inhibitors of PI3K activity and to methods, of using such materials.
BACKGROUND OF THE INVENTION
Cell signaling via 3'-phosphorylated phosphoinositides has been implicated in a
INTRODUCTION
The invention relates to novel hepcidin antagonists of the general formula (I), pharmaceutical compositions comprising these and their use for treatment of iron metabolism disorders, in particular of anaemias in connection with chronic inflammatory diseases (anaemia of chronic disease
TECHNICAL FIELD
This application relates generally to implantable stimulation devices and, more specifically, but not exclusively to providing electrical stimulation to increase the production of erythropoietin.
BACKGROUND
Anemia is defined by the World Health Organization's as hemoglobin
TECHNICAL FIELD
This application relates generally to implantable stimulation devices and, more specifically, but not exclusively to providing electrical stimulation to increase the production of erythropoietin.
BACKGROUND
Anemia is defined by the World Health Organization's as hemoglobin
FIELD OF INVENTION
This invention relates to newly identified polynucleotides, polypeptides encoded by them and to the use of such polynucleotides and polypeptides, and to their production. More particularly, the polynucleotides and polypeptides of the present invention relate to a serine/threonine
FIELD OF THE INVENTION
The present invention relates to novel thiazolidinedione derivatives of omega-3 fatty acids used as insulin sensitizers for treating Type2 diabetes, obesity, hypertriglyceridemia, cardiovascular diseases, metabolic diseases, inflammation, cancer, renal anemia, Alzheimer's
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to the use of interleukin-6 to stimulate the production of endogenous erythropoietin in cells in vitro and in vivo. The invention further includes methods of treatment wherein interleukin-6 is administered to humans
TECHNICAL FIELD OF THE INVENTION
The present invention relates generally to therapy, prevention and amelioration of iron homeostasis disorders. The invention is more specifically related to methods of using BMP-6 and BMP-6 protein-specific reagents, such as antibodies for altering serum iron, serum
STATEMENT REGARDING SEQUENCE LISTING
The Sequence Listing associated with this application is provided in text format in lieu of a paper copy, and is hereby incorporated by reference into the specification. The name of the text file containing the Sequence Listing is
FIELD OF THE INVENTION
The present invention is directed to carbonyl compounds as inhibitors of histone deacetylase (HDAC). These compounds are useful in treatments of disease states, including, but not limited to, certain cancers (such as colon cancer, breast cancer, ovarian cancer, lung cancer,
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a 371 of PCT/EP2016/078726, filed Nov. 24, 2016, which claims the benefit of Italian Application No. UB2016A009994, filed Jan. 14, 2016.
FIELD OF THE INVENTION
The present invention relates to new solid forms of Pomalidomide, in particular